| 1 | 18ο Συνέδριο Ιατρικής Χημείας: Σχεδιασμός και Ανάπτυξη Φαρμακευτικών Προϊόντων, 30-31 Οκτωβρίου 2017, Πάτρα, Ελλάς – 18th Medicinal Chemistry Conference: Drug Discovery and Design, October 30-31, 2017, Patras, Hellas Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 34(2): 51-85 (2020) |
CONTENTS
J. MATSOUKAS………………….…….…………55
Letter from the Guest Editor
CHRISTOS S. ZEREFOS …………….……..….57
Montreal Protocol: 30 years of success
G. R. CHROUSOS ……………………..…..……58
Stress, Genetics and Epigenetics in Human Evolution and Development
J. MATSOUKAS, V. APOSTOLOPOULOS ……60
New Strategies in the immunotherapy of Multiple Sclerosis
A. VALMAS, F. KARAVASSILI, I. MARGIOLAKI ……….62
Macromolecular X-ray Powder Diffraction & Protein-based drug screening: Achievements & Perspectives
V. P. VIDALI …………………………………………..64
Synthesis of natural products and designed organic molecules in anticancer drug development
M. RODI, A. –L. DE LASTIC, A. MOUZAKI ……66
Creation of tolerogenic dendritic cells for individualized therapy in multiple sclerosis patients
C. KALTSI, M. -E. PAPADIMITROPOULOS, T. TSELIOS, M. I. KLAPA …..…68
Using tandem mass spectrometry for metabolite identification in untargeted liquid chromatography-mass spectrometry metabolomics
I. PANAGOULIAS, I. AGGELETOPOULOU, E. KOUREPINI, F. KARAGIANNIS, P. DAVOULOU, P. PAPATHANASOPOULOS, V. PANOUTSAKOPOULOU, A. MOUZAKI …………70
The role of the transcriptional silencer Ets-2 in the pathogenesis of Multiple Sclerosis
C. PAPATHEODOROPOULOS ………………..72
Neurophysiological effects of multiple sclerosis: More than changes in neuronal excitability
S. PARASKEVOPOULOU ………………………….74
Ethical Dilemmas in Clinical Trials for Psychiatric Drugs
E. –P. TSARE, A. GIOUTLAKIS, M. I. KLAPA, N. K. MOSCHONAS ..…….…75
Investigating the Genetic Architecture of Hypertension through Integrated Analysis of Gwas and the Human Protein Interaction Network
A. KAPELLA, P. GKEKA, D. STELLAS, V. P. VIDALI, A. PAPAFOTIKA, S. CHRISTOFORIDIS, Z. COURNIA, E. A. COULADOUROS …………77
Design and Synthesis of Targeted Inhibitors of PI3Kα as Candidate anti- Cancer Drugs
C. CHATZIGIANNIS, A. TZAKOS ………..….…79
A theragnostic device with photo regulated drug dosing and cancer microenvironment sensing character
D. KALOGIANNI, ……………….…….…………..81
Nanotechnology in DNA analysis
E. A. COULADOUROS ……………………………….83
The Architectural Beauty of Bioactive Natural Products
pISSN 1011-6583